Boehringer's Obesity Drug Reduces Harmful Belly and Liver Fat in Late-Stage Trials
Boehringer Ingelheim reported that its experimental obesity drug survodutide significantly reduced harmful abdominal and liver fat in two Phase III clinical trials. The results suggest the treatment may improve metabolic health beyond weight loss, potentially expanding its market appeal.
